Literature DB >> 11927949

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.

Anne M Dickinson1, Xiao-Nong Wang, Lisbet Sviland, Florry A Vyth-Dreese, Graham H Jackson, Ton N M Schumacher, John B A G Haanen, Tuna Mutis, Els Goulmy.   

Abstract

Minor histocompatibility antigens (mHags) are immunogenic peptides from polymorphic cellular proteins that induce strong T-cell responses after human leukocyte antigen (HLA)-matched, mHag-mismatched stem-cell transplantation. mHags with broad or limited tissue expression are target antigens for graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivities. Separation of these activities is crucial for adoptive immunotherapy of leukemia without GvH disease. Therefore, using a skin-explant assay we investigated the in situ activities of cytotoxic T lymphocytes (CTLs) specific for the ubiquitously expressed mHag H-Y and for the hematopoietic-restricted mHags HA-1 and HA-2. H-Y-specific CTLs, visualized by tetrameric HLA-mHag peptide complexes, infiltrated male skin sections within 24 hours, induced severe GvH reactions of grade III-IV and produced high levels of IFN-gamma. In contrast, CTLs specific for the hematopoietic system-specific mHags HA-1 and HA-2 induced no or low GvH reactions above background and produced little or no interferon-gamma, unless the skin sections were preincubated with HA-1/HA-2 synthetic peptides. These results provide the first in situ dissection of GvH effects by mHag-specific CTLs and show that ubiquitously expressed mHags are the prime targets of GvH disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927949     DOI: 10.1038/nm0402-410

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  51 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Authors:  Anthony G Brickner; Anne M Evans; Jeffrey K Mito; Suzanne M Xuereb; Xin Feng; Tetsuya Nishida; Liane Fairfull; Robert E Ferrell; Kenneth A Foon; Donald F Hunt; Jeffrey Shabanowitz; Victor H Engelhard; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

3.  Expanding the immunotherapeutic potential of minor histocompatibility antigens.

Authors:  Eric Spierings; Els Goulmy
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

4.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

5.  Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Authors:  Tetsuya Nishida; Michael Hudecek; Ana Kostic; Marie Bleakley; Edus H Warren; David Maloney; Rainer Storb; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

Review 6.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

7.  Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences.

Authors:  J Michalek; R H Collins; H P Durrani; P Vaclavkova; L E Ruff; D C Douek; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

8.  Donor parity no longer a barrier for female-to-male hematopoietic stem cell transplantation.

Authors:  Astrid G S van Halteren; Miranda P Dierselhuis; Tanja Netelenbos; Mirjam Fechter
Journal:  Chimerism       Date:  2014

Review 9.  The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.

Authors:  Anna Staffas; Marina Burgos da Silva; Marcel R M van den Brink
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.